May 2011
Archives of Disease in Childhood -- Fetal & Neonatal Edition;May2011, Vol. 96 Issue 5, p496
Academic Journal
The article presents updates on medical researches. A U.S. phase II tr ial found that VX-770, a new drug that is an active potentiator of the conductance regulator gene, led to significant improvements in nasal potential difference and reductions in sweat chloride in patients with cystic fibrosis. Particular focus is given to the prevalence of H1N1 in England. A study published in the "New England Journal of Medicine" found that opioid-dependent mothers treated with buprenorphine instea d of methadone experienced less neonatal abstinence syndrome.


Related Articles

  • A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly Adults. Talaat, Kawsar R.; Greenberg, Michael E.; Lai, Michael H.; Hartel, Gunter F.; Wichems, Christine H.; Rockman, Steven; Jeanfreau, Robert J.; Ghosh, M. Rita; Kabongo, Martin L.; Gittleson, Charmaine; Karron, Ruth A. // Journal of Infectious Diseases;11/1/2010, Vol. 202 Issue 9, p1327 

    Background. When the novel H1N1 influenza A strain appeared in April of 2009, development of novel H1N1 vaccines became a public health priority. Methods. We conducted a phase-2, multicenter, randomized, placebo-controlled, observer-blind clinical trial of a 2009 H1N1 vaccine in 1313 young (age,...

  • Lucina.  // Archives of Disease in Childhood;May2011, Vol. 96 Issue 5, p496 

    The article offers information related to diseases. It says that five percent of cystic fibrosis patients has a glycine-for-aspartic acid substitution at amino acid 551 in the cystic fibrosis transmembrane conductance regulator gene (G551D-CFTR). It mentions that influenza A H1N1 reached England...

  • ILI highest among real estate, food service employees.  // Infectious Disease News;Apr2014, Vol. 27 Issue 4, p59 

    The article discusses a U.S. Centers for Disease Control and Prevention (CDC) study, published in a 2014 issue of "Morbidity and Mortality Weekly Report," on the highest prevalence of influenza-like illness (ILI) in real estate and food service workers during the 2009 influenza A(H1N1) pandemic.

  • India Begins Human Clinical Trials for H1N1 Vaccine.  // India -- West;2/12/2010, Vol. 35 Issue 12, pA28 

    The article reports that Serum Institute of India in Pune, India has started clinical trials for its swine flu 2009-H1N1 influenza vaccine after getting permission from the Drugs Controller General of India.

  • Big Drugmakers Start Trials of Swine Flu Vaccines.  // Clinical Infectious Diseases;10/1/2009, Vol. 49 Issue 7, pi 

    The article reports that giant drug manufacturers such as GlaxoSmithKline, Novartis, and Sanofi Aventis have started their clinical trials for the H1N1 swine flu vaccine.

  • Triple oseltamivir dose resulted in rapid clearance of H1N1. Cox, Amber; Schoen, John; Shafer, Emily // Infectious Disease News;Oct2013, Vol. 26 Issue 10, p21 

    The article discusses research on the effectiveness of a triple dose of oseltamivir in treating patients with H1N1 influenza A, presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Denver, Colorado on September 10-13, 2013.

  • Pandemic flu: will there be a second wave? Godlee, Fiona // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/22/2009, Vol. 339 Issue 7718, p408 

    The article discusses various papers published within the issue including one about the safety, effectiveness and tolerability of oseltamivir and zanamivir, and another about the lessons learned on how Australia addressed influenza A/H1N1.

  • Ring prophylaxis contained influenza A (H1N1) outbreaks.  // Infectious Disease News;Jul2010, Vol. 23 Issue 7, p12 

    This article reports on a study on the effectiveness of a geographically targeted method of administering preventive oseltamivir in reducing the number of influenza A (H1N1) cases.

  • Oseltamivir/zanamivir.  // Reactions Weekly;1/9/2010 Part 2 of 2, Issue 1283, p71 

    The article describes the case of a 37-year-old woman who died from novel influenza A (H1N1) infection due to inefficacy of oseltamivir and zanamivir.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics